From the Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
D000881:Anthrax / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000009:adverse effects; D001408:Bacillus anthracis; D023482:Bioterrorism; D002939:Ciprofloxacin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008402:Mass Media; D009784:Occupational Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D016273:Occupational Exposure; D011177:Postal Service; D015980:Public Health Practice; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D017192:Skin Diseases, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D013171:Spores, Bacterial; D016312:Treatment Refusal; D014481:United States / Q000453:epidemiology
D000890:Anti-Infective Agents; D002939:Ciprofloxacin